[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplams\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplams":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,76,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100643247","phase-1-phase-1-study-of-mst-168-in-participants-with-advanced-solid-malignant-tumors-100643247",false,"NCT07644650","Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors","A Phase 1, Multiregional, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MST-168, in Participants With Advanced Solid Malignant Tumors","Inclusion Criteria:\n\n* Participants are eligible to be included in the study only if all of the following criteria apply:\n\nI1. Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nI2. Is at least 18 years of age at the time of signing the ICF.\n\nI3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nI4. Life expectancy ≥ 12 weeks.\n\nI5. Has adequate organ function.\n\nI6. Pregnancy and Contraception: Female participants agree not to be pregnant or lactating from beginning of the study screening until 6 months after receiving the last treatment. Male participants with partners of childbearing potential and female participants of childbearing potential are willing and able to employ a highly effective method of birth control\u002Fcontraception to prevent pregnancy from beginning of the study screening until 6 months after receiving the last treatment of MST-168.\n\nI7. Has a pathologically documented advanced\u002Funresectable or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\nE1. Has untreated brain or CNS metastases or brain\u002FCNS metastases that have progressed \\[e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain\u002FCNS metastases\\]. Participants with previously unstable brain or CNS metastases.\n\nE2. Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \\[e.g., breast, cervix, bladder\\] that have been resected with no evidence of metastatic disease.\n\nE3. Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.\n\nE4. Has known sensitivity to study intervention components or excipients.","ALL","18 Years",{"count":19,"type":20},420,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors.\n\nThe goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.",[26],"Neoplams",[28,29],"advanced solid tumors","ADC","NOT_YET_RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":20},"2026-06-15",{"date":38,"type":20},"2030-06-30",{"name":40,"class":41},"Mabsoft Therapeutics (Shanghai) Co., Ltd.","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100605812","xdrive-for-florida-based-cancer-patients-100605812","NCT07167381","xDRIVE for Florida-based Cancer Patients","xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed\u002F Refractory Cancers","Inclusion Criteria:\n\n* Patients with recurrent\u002Frefractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)\n* -OR- Patients with recurrent\u002Frefractory cancer ≥18 years of age.\n* Patients who have received at least one prior line of standard of care therapy.\n* Patients able to provide treatment and outcome information from previous line(s) of therapy.\n* Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.\n* Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.\n* Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.\n\nExclusion Criteria:\n\n* Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and\u002For genetic profiling, defined as \\\u003C0.3g for resections or core\u002Ffine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.\n* Patients with insufficient health indicators to undergo therapeutic intervention.",{"count":50,"type":20},210,[52],"NA","Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).",[55,26,56,57,58,59,60,61],"Cancer","Refractory","Recurrence","Leukaemia","Lymphoma","Solid Tumor Malignancies","Solid Cancers",[63,64],"Functional Precision Medicine","Artificial Intelligence","RECRUITING","2026-05-17",{"date":68,"type":34},"2026-05-19",{"date":70,"type":34},"2025-11-01",{"date":72,"type":20},"2027-04-01",{"name":74,"class":41},"First Ascent Biomedical Inc.",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100630363","phase-1-the-phase-i-study-of-sig001-antibody-on-cancer-therapy-100630363","NCT07486700","The Phase I Study of SIG001 Antibody on Cancer Therapy.","An Open-label, Phase I, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SIG001 in Subjects With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria to be eligible for this clinical study:\n\n  1. The subject must fully understand the requirements of this study and voluntarily sign a written informed consent form. They must also be able to comply with the study's medication regimen as well as all related procedures and assessments;\n  2. Age must be \\>=18 and \\\u003C=75 years old, with no gender restriction;\n  3. Subjects must have locally advanced, recurrent, or metastatic malignant tumors that have failed standard treatment or are not tolerant to it, and for which there is no effective standard treatment option. Histological or cytological confirmation is required;\n  4. According to RECIST v1.1, the subject must have at least 1 measurable target lesion. At baseline, the lesion must be accurately measurable by computed tomography (CT) or magnetic resonance imaging (MRI) - preferably with intravenous contrast agent. The long diameter of non-lymph node lesions must be ≥10 mm, and the short axis of lymph node lesions must be \\>=15 mm. The lesion must be suitable for repeated and accurate measurements. If a lesion in a previously irradiated area shows clear progression, it can also be considered a measurable target lesion;\n  5. The expected survival time must be \\>=12 weeks;\n  6. The Eastern Cooperative Oncology Group performance status score must be 0 or 1;\n  7. Subjects must have adequate function of vital organs at the time of screening. This requires that no blood transfusions, hematopoietic stimulants, or human albumin preparations have been used within 14 days prior to screening. The specific criteria are as follows:\n\n  \u003C!-- -->\n\n  1. Blood tests: Absolute neutrophil count \\>=1.5 × 10\\^9\u002FL; Platelet count \\>=75 × 10\\^9\u002FL; Hemoglobin \\>=90 g\u002FL;\n  2. Liver function: Serum TBIL \\\u003C=1.5 × ULN. For patients with liver metastases or Gilbert's syndrome, TBIL \\\u003C=3 × ULN. For subjects without liver metastases, ALT and AST \\\u003C=2.5 × ULN; for those with liver metastases, ALT and AST \\\u003C=5 × ULN;\n  3. Coagulation function: Activated partial thromboplastin time and International normalized ratio \\\u003C=1.5 × ULN (for subjects on anticoagulant therapy, these values must be within the therapeutic range).\n  4. Renal function: Creatinine clearance rate \\>=60 mL\u002Fmin, calculated using the Cockcroft-Gault formula;\n  5. Cardiac function: Echocardiography shows left ventricular ejection fraction greater than 50%; 8. Female subjects of childbearing age must have a negative pregnancy test within 7 days before receiving the study drug for the first time. Eligible male and female subjects must agree to use reliable contraceptive methods (hormonal, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of the drug. Eligible subjects are defined as being sexually mature and biologically capable of reproducing.\n\nExclusion Criteria:\n\n* Subjects will be excluded if they meet any of the following criteria:\n\n  1. SIG001 is administered during the washout period following previous antineoplastic therapy (4 weeks or 5 half-lives after the last dose, whichever is shorter);\n  2. Received radiotherapy within 28 days prior to the first dose of SIG001;\n  3. Acute toxicity resulting from previous antineoplastic therapy had not resolved to NCICTCAE 5.0 version grade ≤1 or to the baseline level specified in the inclusion criteria 4 weeks before the first dose of SIG001 (excluding hair loss or fatigue);\n  4. Had a history of other malignant tumors within 5 years prior to the first dose (except for non-melanoma skin basal cell carcinoma or squamous cell carcinoma that has been cured with no evidence of recurrence, breast\u002Fcervical carcinoma in situ, superficial bladder carcinoma, and other in situ cancers);\n  5. Subjects with any of the following cardiovascular diseases:\n\n  \u003C!-- -->\n\n  1. Symptomatic heart failure (New York Heart Association functional class \\>=2, see Appendix 4);\n  2. Uncontrolled hypertension despite standard treatment (systolic blood pressure \\>=160 mmHg or diastolic blood pressure \\>=100 mmHg);\n  3. Resting mean corrected QT interval \\> 470 ms on a 12-lead electrocardiogram (QTc, using Fridericia's correction formula) on three repeated measurements. Various clinically significant arrhythmias, conduction abnormalities, and resting ECG abnormalities, such as complete left bundle branch block, third-degree block, second-degree block, and PR interval \\> 250 ms. Factors that may increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or sudden death before age 40, and use of medications known to prolong QTc;\n  4. Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening;\n  5. Any cause of cardiomyopathy;\n  6. Clinically significant valvular heart disease;\n  7. History of atrial or ventricular arrhythmias that require treatment; subjects with atrial fibrillation and well-controlled ventricular rate may be enrolled;\n  8. Transient ischemic attack or stroke within 6 months prior to screening; 6. Subjects with infectious diseases, including;\n\n  \u003C!-- -->\n\n  1. Acute or chronic active hepatitis B, defined as positive for hepatitis B surface antigen (HbsAg) and\u002For hepatitis B core antibody (HbcAb) with HBV DNA \\>=100 IU\u002FmL;\n  2. Acute or chronic active hepatitis C, i.e., positive for HCV antibodies with HCV-RNA levels above the upper limit of the central reference range;\n  3. HIV-infected individuals (positive for HIV 1\u002F2 antibodies);\n  4. Active syphilis or active pulmonary tuberculosis; 7. Subjects with primary central nervous system tumors, meningeal metastases, spinal cord compression, or brainstem metastases; those with untreated brain metastases or symptomatic\u002Fstable conditions can be enrolled after at least 4 weeks of stable treatment; 8. Uncontrolled comorbidities, such as:\n\n  \u003C!-- -->\n\n  1. Severe infections within 4 weeks prior to study initiation, including hospitalization due to infection, bacteremia, or severe pneumonia; subjects with uncontrolled active infections during screening can be enrolled if they receive prophylactic antibiotics (e.g., for urinary tract infections or chronic obstructive pulmonary disease);\n  2. History of interstitial lung disease, unresolved radiation pneumonitis, acute episodes or progressive worsening of pulmonary symptoms at baseline, or factors that increase the risk of interstitial lung disease and pose a safety risk to the subject as assessed by the investigator;\n  3. Severe malnutrition requiring intravenous nutrition; subjects whose malnutrition has been corrected and stabilized for more than 4 weeks prior to the first dose can be enrolled;\n  4. Tumors invading vital organs or blood vessels, which may significantly increase treatment risk or affect efficacy assessment; subjects with a risk of esophagotracheal fistula or esophagothoracic fistula, or those within 4 weeks of esophageal or tracheal stent placement (subjects with stable conditions for more than 4 weeks can be enrolled);\n  5. History of gastrointestinal perforation and\u002For fistula within 6 months prior to screening;\n  6. Presence of uncontrolled effusions requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Subjects without the need for drainage or with no significant increase in effusion volume after 3 days of drainage cessation can be enrolled).\n\n  9\\. Subjects who are expected to receive other antineoplastic treatments during the study period (palliative radiotherapy is allowed); 10. Subjects who have participated in clinical studies within 4 weeks prior to the first dose or plan to participate in other clinical studies during the study period; 11. Subjects who have received live vaccines within 4 weeks prior to the first dose; 12. Allergy to SIG001 or its components; 13. Pregnant women, lactating women, or women who plan to become pregnant during the study period; 14. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 15. Subjects who have received systemic immunosuppressive therapy for autoimmune diseases within 2 years prior to dosing are excluded, except in the following cases:\n  1. Inhaled, topical, or intramuscular steroid use;\n  2. Systemic corticosteroids (dose not exceeding 10 mg\u002Fday of prednisone or equivalent);\n  3. Steroids used as premedication for hypersensitivity reactions (e.g., premedication for CT scans).\n\n  16\\. Subjects with a history of mental disorders and those taking medication for treatment; 17. Subjects with a history of drug abuse or substance use; 18. Subjects who, in the judgment of the investigator, have other factors that may affect the study results or interfere with their participation in the entire study, including past or current health conditions, treatment or laboratory test abnormalities, and those who are unwilling to comply with the study procedures and requirements.","75 Years",{"count":85,"type":20},66,[23],"The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics of SIG001. The main questions it aims to answer are:\n\nWhat is the safety and tolerability of SIG001 in patients with advanced solid tumors ? What is the Recommended Phase II dose of SIG001? What is the PK\u002FPD characteristics of SIG001 in cancer patients? What is the antitumor activity of SIG001 in cancer patients? What is the immunogenicity of SIG001 in cancer patients? What is the relationship between the exposure\u002Fdose of SIG001 and its safety as well as clinical efficacy? What is the expression levels of potential biomarkers (such as SIG), if applicable, and analyze their correlation with drug exposure, efficacy, and safety? What is event-related endpoints such as the Duration of Response and Progression-Free Survival in patients treated with SIG001?\n\nThis will be a single-armed study.\n\nParticipants will:\n\nIntravenously Inject SIG001 every two weeks, for 4 weeks Visit the clinic on the 14th day, 30th day, and 90th day afer the last injection. Then visit the clinic for every 12 weeks.",[26],[90,91,92],"neoplams","tumor IgG","sialylated IgG","2026-03-17",{"date":95,"type":34},"2026-03-20",{"date":97,"type":20},"2026-03",{"date":99,"type":20},"2028-07",{"name":101,"class":102},"Peking University","OTHER",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":111,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":103},"100628350","plyometric-strength-endurance-exercise-in-breast-cancer-100628350","NCT07460492","Plyometric Strength-Endurance Exercise in Breast Cancer","Therapeutic Plyometric-Based Strength-Endurance Exercise Program for Breast Cancer Patients and Survivors to Improve Quality of Life and Physical and Mental Function","Inclusion Criteria:\n\n* Women aged 18 years or older.\n* Prior diagnosis of breast cancer.\n* History of mastectomy, including unilateral procedures, total breast surgery, or breast-conserving surgery.\n* Completion of postoperative chemotherapy or radiotherapy, when indicated.\n* Absence of contraindications for physiotherapy or therapeutic exercise.\n* Willingness to voluntarily participate in the study.\n* Ability to understand and sign the informed consent form.\n* Availability to participate in the training program for the entire intervention period (approximately 12 weeks).\n\nExclusion Criteria\n\n* Participants will be excluded if any of the following conditions are present:\n* Active metastasis to other organs or tissues (e.g., liver, kidney, lung, brain) or stage IV cancer that prevents safe participation in the therapeutic exercise program.\n* Current diagnosis of cardiovascular, respiratory, neuromuscular, or musculoskeletal diseases that contraindicate physical exercise or impair safe completion of the program.\n* Major surgery within the previous 6 months without medical clearance to resume physical activity.\n* Cognitive impairment or mental health conditions that limit comprehension of instructions or safe engagement in the intervention.\n* Current pregnancy.\n* Lack of medical clearance for moderate-to-vigorous physical activity (as indicated by a medical certificate specifying the duration of the restriction and the conditions under which exercise may be resumed).","FEMALE",{"count":113,"type":20},51,[52],"This study aims to compare an adapted plyometric strength-endurance exercise program with conventional strength training in women who are breast cancer survivors or currently undergoing treatment and who participate in provincial support associations. The goal is to determine whether a targeted plyometric intervention can provide additional benefits in physical and mental health outcomes.\n\nUsing a cluster-randomized clinical trial design, the study will assess indicators such as functional capacity, muscle strength, fatigue levels, symptoms related to lymphedema, and overall quality of life. The findings are expected to contribute to a better understanding of how structured exercise programs can support recovery, physical function, and well-being in women affected by breast cancer.",[26,117,118],"Patients","Cancer Survivors",[120,121,122,123,124,125],"Randomized Controlled Trial","Cluster Analysis","quality of life","physical functional performance","functional status","mental health","2026-03-10",{"date":128,"type":34},"2026-03-13",{"date":130,"type":20},"2026-04-20",{"date":132,"type":20},"2027-12-31",{"name":134,"class":102},"University of Vigo"]